Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1654 1658
This examiner grants 33% of resolved cases
Sara Elizabeth Konopelski Snavel is an examiner in Tech Center 1600 and Art Unit 1631. She has resolved 39 cases, which is a small sample size. Her allowance rate is 33.3 percent, suggesting a challenging prosecution environment for applicants.
The interview lift for this examiner is 38.9 percent. This positive lift indicates that an interview can be a tool for moving an application toward allowance, even when the base allowance rate is 33.3 percent. Practitioners should consider the 38.9 percent lift as a tactical option when facing rejections in Art Unit 1631.
The median days to allowance is 1370, which is a long pendency period. This 1370-day median reflects the time required to navigate the process, especially given the 39 resolved cases currently on record. Practitioners should focus on the 38.9 percent interview lift to potentially improve both the outcome and the efficiency of prosecution in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19378410 | SEMAGLUTIDE IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE | Final Rejection | Novo Nordisk A/S |
| 17785561 | STRUCTURALLY-STABILIZED ONCOLYTIC PEPTIDES AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18612180 | METHODS OF PRODUCING FC-CONTAINING PROTEINS | Non-Final OA | ELI LILLY AND COMPANY |
| 18799107 | De novo designed sequence-specific DNA binding proteins | Non-Final OA | University of Washington |
| 18515425 | COMPOSITION FOR ANTI-FATIGUE COMPRISING GREEN TEA PEPTIDE COMPOSITION | Non-Final OA | AMOREPACIFIC CORPORATION |
| 17999235 | COMPOSITIONS AND METHODS FOR PREVENTION OF CORONAVIRUS INFECTION | Final Rejection | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 17788847 | AGENT FOR ADJUVANT THERAPY | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 18447414 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | Final Rejection | Peptilogics, Inc. |
| 17282661 | THERAPEUTIC USE OF GLUCAGON AND COMBINATION INCLUDING THE SAME | Non-Final OA | HANMI PHARM. CO., LTD |
| 18284374 | EMBOLIC MATERIAL FOR RELIEVING OR TREATING MUSCULOSKELETAL PAIN COMPRISING FAST DISSOLVING GELATIN PARTICLES | Final Rejection | ENGAIN CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy